ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1804

Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus

Ananta Subedi1, Hong Fang2 and Michelle Petri2, 1Good Samaritan Hospital, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Infection, mycophenolate mofetil and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs

Session Type: Abstract Submissions (ACR)

Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of infection, or both. The aim of this study was to analyze the effect of mycophenolate on the white blood cell count and the rate of infection in SLE patients.

Methods: Three hundred patents within the Hopkins Lupus Cohort who were on mycophenolate mofetil were included in the study. SLE patients served as their own control (before and after mycophenolate mofetil). The white blood cell count and rate of infection were compared on the day mycophenolate was started with the white blood cell count and rate of infection at the next visit. Statistical analysis was performed using the paired t-test.

Results:

At the time of the analysis, three hundred patients in the cohort were taking mycophenolate mofetil. The study population included 43% Caucasians, 47% African-Americans and 10% other ethnicities. There was a slight but not statistically significant increase in the white blood cell count (6.65±3.34 vs. 7.02±3.28, P= 0.075), after starting mycophenolate. Patients with a baseline white blood cell count less than 3,000/mm3 did have a statistically significant increase in the white blood cell count after starting mycophenolate mofetil (2.49±0.46 vs. 4.83±2.66, P= 0.0007). In the multivariate model for factors associated with the white blood count, mycophenolate use was not statistically significant (Table 1). We also found a statistically significant increase in the rate of bacterial infection (but not viral infection) after starting mycophenolate mofetil (5% vs. 9%, P= 0.032, Table 2).

Table 1. Factors Associated with the White Blood Cell Count Adjusted for Ethnicity and Prednisone dose.

 

Variable

Effect on white blood cell Count

p-value

Ethnicity

 

 

African-American vs. Caucasian

-0.91±0.33

0.0049

Other ethnicity vs. Caucasian

-0.52±0.51

0.31

Prednisone (per mg/d)

0.07±0.01

<0.0001

Mycophenolate mofetil

(before vs. after)

0.20±0.18

0.28

Table 2. Frequency of Infection Before and During the Use of Mycophenolate mofetil.

           

Variable

Before mycophenolate mofetil (%)

After mycophenolate mofetil (%)

Adjusted p-value*

Infection (viral or bacterial)

14

18

0.087

Viral infection

10

10

0.17

Bacterial infection

5

9

0.032

* p-value adjusted for prednisone dose.

Conclusion: Leukopenia does not worsen with mycophenolate. However, mycophenolate does increase the rate of bacterial (but not viral) infection.


Disclosure:

A. Subedi,
None;

H. Fang,
None;

M. Petri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-mycophenolate-on-the-white-blood-cell-count-and-the-frequency-of-infection-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology